Equillium, Inc. (EQ) earnings
EQ earnings moved a median of -7.35% by the close. Quarterly and annual EQ reports and results, each read against the price at its own news timestamp. Back to the EQ overview →
18 measured EQ earnings events.
Where these EQ earnings landedvs 18 measured EQ earnings reactions
| Middle 50% of EQ earnings reactions | -9.41% to +11.38% |
|---|---|
| Median reaction (to close) | -7.35% |
| Measured reactions | 18 |
Point-in-time · zero look-ahead
Half of the 18 EQ earnings events with a measured close landed between -9.41% and +11.38%; 33% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Equillium Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights | Press release | -1.97% | +16.26% | |
| Form 10-Q Equillium, Inc. For: Jun 30 | SEC filing · Form 10-Q | -1.97% | +16.26% | |
| Equillium Reports First Quarter 2026 Financial Results and Corporate Highlights | Press release | +1.12% | +15.63% | |
| Form 10-Q Equillium, Inc. For: Mar 31 | SEC filing · Form 10-Q | +1.12% | +15.63% | |
| Form 10-K Equillium, Inc. For: Dec 31 | SEC filing · Form 10-K | +1.00% | +3.52% | |
| Form 10-Q Equillium, Inc. For: Jun 30 | SEC filing · Form 10-Q | -2.01% | +14.00% | |
| Form 10-Q Equillium, Inc. For: Mar 31 | SEC filing · Form 10-Q | -10.15% | -6.81% | |
| Form 10-K Equillium, Inc. For: Dec 31 | SEC filing · Form 10-K | +3.02% | -2.40% | |
| Equillium Reports Third Quarter 2024 Financial Results and Provides Corporate and Clinical Updates | Press release | +0.00% | -9.97% | |
| Form 10-Q Equillium, Inc. For: Sep 30 | SEC filing · Form 10-Q | +0.00% | -9.97% | |
| Equillium Reports Second Quarter 2024 Financial Results and Provides Recent Corporate and Clinical Highlights | Press release | -3.70% | -7.89% | |
| Form 10-Q Equillium, Inc. For: Jun 30 | SEC filing · Form 10-Q | -3.70% | -7.89% | |
| Equillium Announces Second Quarter 2024 Estimated Cash and Investments Balance | Press release | -1.06% | -0.50% | |
| Equillium Reports First Quarter 2024 Financial Results and Provides Recent Clinical Highlights | Press release | -6.08% | -19.05% | |
| Form 10-Q Equillium, Inc. For: Mar 31 | SEC filing · Form 10-Q | -6.08% | -19.05% | |
| Form 10-K Equillium, Inc. For: Dec 31 | SEC filing · Form 10-K | +1.77% | -8.85% | |
| Equillium Reports Third Quarter 2023 Financial Results and Provides Corporate and Clinical Updates | Press release | -2.29% | -9.41% | |
| Form 10-Q Equillium, Inc. For: Sep 30 | SEC filing · Form 10-Q | -2.29% | -9.41% |
Keep exploring
More EQ: analyst actions → · SEC filings → · EQ overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Fortress Biotech, Inc. (FBIO) | 235 | -0.68% | 37% |
| Rockwell Medical, Inc. (RMTI) | 235 | +0.40% | 57% |
| Eton Pharmaceuticals, Inc. (ETON) | 234 | -0.34% | 40% |
| THERAPIX BIOSCIENCES LTD AMERICAN DEPOSITARY SHARE (TRPX) | 234 | -1.05% | 31% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.